At present, AD diagnosis mainly relies on MMSE score, 18FDG-PET, CT, or MRI scanning, and identification of T-tau, p-tau, Aβ42, and other biomarkers in the cerebrospinal fluid (Hane et al., 2017; Wolinsky et al., 2018; Guest et al., 2020). Here, MAPT is linked to Alzheimer disease.